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Context: Sphingolipids function as key bioactive mediators that regulate cell fate events in a
variety of systems. Disruptions in sphingolipidmetabolism characterize several human pathologies.
Objective: In the present study we examined sphingolipid metabolism in intrauterine growth
restriction (IUGR),a severedisorder complicating4–7%ofpregnanciesat increasedriskofperinatal
morbidity and mortality, which is characterized by placental dysfunction and augmented tropho-
blast cell death rates.
Design, Setting, and Participants: Placentae from early severe IUGR with documented abnormal
umbilical artery Doppler defined as absence or reverse of end diastolic velocity and a birth weight
below the fifth percentile for gestational age were collected (n  58). Placental tissues obtained
from healthy, age-matched preterm and term deliveries (n  46; TC, n28) were included as
controls.
Results: Sphingolipid analysis by tandem mass spectrometry revealed elevated sphingosine and
decreased ceramide levels in placentae from pregnancies complicated by IUGR relative to age-
matched controls. Sphingosine accumulation was due to accelerated ceramide breakdown via
increased acid ceramidase (ASAH1) expression/activity caused by augmented TGF signalling via
the ALK5/SMAD2 pathway. In addition, a marked reduction in sphingosine kinase 1 (SPHK1) ex-
pression/activity due to impaired TGF signalling via ALK1/SMAD1 contributed to the sphingosine
buildup in IUGR.Of clinical significance,ALK/SMADsignallingpathwaysweredifferentially altered
in IUGR placentae.
Conclusions: Altered TGF signalling in IUGR placentae causes dysregulation of sphingolipid me-
tabolism, which may contribute to the increased trophoblast cell death typical of this pathology.
(J Clin Endocrinol Metab 100: E986–E996, 2015)
Sphingolipids are ubiquitous components of all eukary-otic cell membranes that, in addition to being struc-
tural elements, function as important bioactive mediators
in a variety of cell events governing cell death and prolif-
eration (1, 2). At the core of sphingolipid metabolism is
ceramide (CER),which is the only sphingolipid that canbe
synthesized de novo in the endoplasmic reticulum. Once
synthesized,CER is transported toanumberof subcellular
compartments where it can be converted into other sph-
ingolipid species via the action of sphingolipid regulatory
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enzymes. In the lysosome, acid ceramidase (ASAH1) is
responsible for hydrolyzing CER into sphingosine (SPH),
which in turn is converted into sphingosine-1-phosphate
(S1P) by sphingosine kinases (SPHK1/2). The regulation
of the ASAH1/SPHK1 axis is vital for cell homeostasis as
S1P promotes cell survival whereas SPH and CER trigger
cell death.Heritable deficiencies inASAH1activity caused
by mutations in the gene encoding the enzyme (ASAH1)
can result in Farber disease, a lysosomal storage disor-
der characterized byCER accumulation (3). In contrast,
enhanced ASAH1 activity is present in cancers and Alz-
heimer’s disease, thereby decreasing CER levels (3, 4).
Similarly, aberrant SPHK1 expression promotes tumor-
igenesis (5). Consequently, ASAH1 and SPHK1 are crit-
ical to maintenance of sphingolipid metabolism as dis-
ruptions to their expression/activity can result in serious
pathologies.
Early placental development is characterized by a tight
coordination of proliferation, differentiation and apopto-
sis of trophoblast cells. In vitro studies have implicated
sphingolipids in trophoblast cell fusion (6), underscoring
their importance in the developing placenta. Members of
the TGF superfamily play key roles in regulating tropho-
blast cell fate (7–9); however, the interplay between
TGFs and sphingolipid metabolism remains largely un-
explored. It has been reported that TGF1 reduces CER
production of mouse embryonic fibroblast cells, thereby
suppressing apoptosis (10). Others have reported a de-
crease in CER levels in human dermal fibroblasts after
TGF1 exposure (11) that was accompanied by an aug-
mented expressionof SPHK1 leading to S1Paccumulation
(12). Yet, no information is available on the role of TGFs
in regulating sphingolipid metabolism in the human pla-
centa and its contribution to placental pathology.
Intrauterine growth restriction (IUGR) is a serious
complication of pregnancy that is linked to placental in-
sufficiency. Although unanimous agreement over the clas-
sification and etiology of IUGR is lacking, IUGR is com-
monly defined as failure of the fetus to achieve its growth
potential and is associated with a birth weight below the
10th percentile for gestational age (13). However; more
stringent criteria including fetal weight values below
fifth or even third percentile together with measure-
ments of abdominal circumference are often used for
IUGR diagnosis and management. IUGR affects ap-
proximately 4–7%of births and results in increased risk
of perinatal morbidity and mortality (13). Placentae
from IUGR pregnancies are characterized by increased
trophoblast cell death and impaired trophoblast inva-
sion resulting in inadequate maternal vascular remod-
elling, leading to poor uteroplacental perfusion and fe-
tal development (14, 15). We have recently reported
that sphingolipid metabolism is altered in preeclampsia
(16), another pregnancy-related disorder characterized by
maternalhypertension. Inparticular,weshowthat increased
de novo CER synthesis and reduced ASAH1 expression/ac-
tivity results in CER overload in pre-eclampsia leading to
increased trophoblast cell autophagy (16). Although IUGR
andpreeclampsia share a number ofmorphological andmo-
lecular features suggestive of altered trophoblast cell death
rates, thecontributionofbioactive sphingolipidmediators to
the pathogenesis of IUGR remains to be established. Hence,
in the current study, we examined the sphingolipid metab-
olism in IUGR.
Materials and Methods
Placental tissue collection
Informed consent was obtained from all participants. Tissue
collection was performed by the Biobank of Mount Sinai Hos-
pital and by the Sant’Anna Hospital, University of Turin, Italy,
in accordance with the Institutions’ ethics guidelines. Early ges-
tationplacental tissues (5–8wkgestation; n12)were obtained
from elective termination of pregnancies. Placental tissue ob-
tained from IUGR pregnancies (n  58) were selected based on
the American College of Obstetricians and Gynaecologists clin-
ical and pathological criteria (13). All womenwere healthy non-
smokers who did not consume alcohol during pregnancy.
Women did not have signs of pre-eclampsia, essential hyperten-
sion, infection, or known causes of IUGR including renal, en-
docrine, and autoimmune disorders. IUGR fetuses exhibited a
birthweight below the fifth percentile. Placental tissues collected
from healthy, gestational age–matched preterm (PTC, n  46)
and term (TC, n  28) deliveries with normally grown fetuses
that did not have signs of other placental dysfunctions were in-
cluded as controls. Cervical incompetence, idiopathic labor, and
preterm premature rupture of membranes were casual for pre-
term deliveries. Control and pathological tissues were collected
from singleton pregnancy that did not exhibit any fetal anoma-
lies and chromosomal abnormalities. Patients’ information, in-
clusion criteria, and clinical parameters are outlined in Supple-
mental Table 1.
First trimester villous explant culture
Human villous explant cultures were performed from first
trimester human placental tissue (5–8 wk gestation) as previ-
ously described (17). For detailed culture and treatments proce-
dures see Supplemental Materials.
Choriocarcinoma cell cultures
Human choriocarcinoma JEG3 cells were seeded at a density
of 1.5  105 cells per well into six-well plates and cultured in
complete EMEM media (ATCC) supplemented with 10% (v/v)
heat-inactivated fetal bovine serum at 37°C in standard condi-
tions (5% CO2 in 95% air) as previously described (14). For
detailed culture and treatment conditions see Supplemental
Materials.
doi: 10.1210/jc.2015-1288 press.endocrine.org/journal/jcem E987
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 07 June 2016. at 00:53 For personal use only. No other uses without permission. . All rights reserved.
Transient transfection studies
Smad2 was knocked down in JEG3 cells using a Smad2
siRNA-containing plasmid kindly provided by Dr Chun Peng
(YorkUniversity, Toronto, Canada). For detailed procedures on
transfection see Supplemental Materials.
Mass spectral analysis
Placental tissues from IUGR, PTC pregnancies, and villous
explants were collected, processed for lipid extraction, and sph-
ingolipidomic analysis was conducted at the Analytical Facility
for Bioactive Molecules at The Hospital for Sick Children, To-
ronto, Canada. Lipid extraction was performed according to
Bligh and Dyer (18). Sphingolipids were then analyzed using
high-performance liquid chromatography coupled to a tandem
mass spectrometer (LC-MS/MS) as previously described (16).
RNA analysis
Total RNA was extracted from frozen placental tissue and
JEG3 cells using TRIzol and treated with DNase I to remove
genomic DNA contamination. Next, RNA was reverse tran-
scribed using randomhexamers (Applied Biosystems) and am-
plified by PCR. Analysis was performed using the DNA En-
gine Opticon 2 System (MJ Research) as previously described
(19). TaqMan Universal MasterMix and specific TaqMan
primers and probes for ASAH1, SPHK1, and 18S were pur-
chased from ABI as Assays-on-Demand for human genes.
Data were normalized against expression of 18S rRNA using
the 2Ct formula (19).
Antibodies and Western blot analysis
Western blotting was performed as previously described
(19). For details on procedures, reagents, and antibodies used
see Supplemental Materials.
Immunohistochemistry and immunofluorescence
staining
Immunohistochemical and immunofluorescence analyses
were performed in tissue sections from IUGR and PTC as pre-
viously described (8, 14).
ASAH1 and SPHK1 activity measurements
ASAH1 activity was measured as described previously (16).
SPHK1 activity was assessed using an Echelon SPHK1Assay Kit
(K-3500) according to the manufacturer’s protocol (Echlon
Bioscience).
Statistical analysis
Statistical analysis was performed using GraphPad Prism 4
software. For comparison of two groups an unpaired t test was
used with or without Welch’s correction, where applicable. For
comparison between multiple groups, one-way ANOVA with
post-hoc Student-Newman-Keuls test was performed or two-
way ANOVA with post-hoc Bonferroni test, where applicable.
Statistical significance was defined as P  .05 and results are
expressed as the mean  SEM.
Results
Ceramide metabolism is disrupted in IUGR
pregnancies
We first measured sphingolipid levels in placental tis-
sue from IUGR pregnancies and PTC using LC-MS/MS.
Characteristics of the study population are summarized
in Supplemental Table 1. Lipidomic analyses revealed
significantly decreased levels in ceramide species C18-
Cer(d18:1/18:0), C20-Cer(d18:1/20:0), and C24-
Cer(d18:1/24:0) in IUGR placentae relative to PTC
(Figure 1A). No changes in C16-Cer(d18:1/16:0) levels
were observed between groups. Tissue CER levels are
maintained by a balance between their rates of synthesis
and breakdown, which is highly dependent on the ac-
tivity of specific enzymes. Sphinganine and dihydrocre-
amide (eg, DHcerC24) levels (de novo-precursors of cer-
amides) were increased in IUGR (Supplemental Figure 1)
suggesting an increase in de novo ceramide pathway. This
observation together with the decreased CER levels is
highly suggestive of enhanced CER turnover in IUGR pla-
centae. Given that total sphingomyelin levels did not
change in IUGR vs PTC placentae (Supplemental Figure
1),we postulated that an increased degradation ofCERby
ASAH1andnot an increased conversionof sphingomyelin
into CER via sphingomyelinase was responsible for the
reduced CER levels. ASAH1 is synthesized as a 55-kDa
precursor protein that undergoes autoproteolytic cleavage
in the lysosome, producing a 53-kDa dimeric active form
(20). Western blot analysis of human placental lysates iden-
tified ASAH1 as a band with a molecular mass of 40 kDa,
corresponding to the molecular weight of the -subunit of
the active enzyme (Figure 1, B and C). Specificity of the
ASAH1 antibody was validated using a blocking peptide
(Figure 1B). In agreement with decreased CER levels in
IUGR,we found augmented ASAH1 protein levels in IUGR
placentae relative to PTC (Figure 1C), as well as increased
ASAH1 activity (Figure 1D). It should be noted that labor,
gestation, and sex did not affect placental ASAH1 protein
expression (Supplemental Figure 2, A and B). Immunohis-
tochemical stainingrevealedstrongpositiveASAH1signal in
the trophoblast layer of IUGR placentae (Figure 1E). Low
positive immunoreactivity was observed in PTC sections,
whereas no signal was detected in nonimmune IgG control.
Collectively, these findings suggest enhanced breakdown of
CER to sphingosine by ASAH1 in IUGR placentae.
Signalling via ALK5 regulates ASAH1 expression
IUGR is characterized by sustained placental hyp-
oxia and elevated TGF expression, which contributes
to the placental dysfunction typical of this pathology
(15, 21). Hence, we examined the effect of TGF on
ASAH1 expression in human choriocarcinoma JEG3
cells, an established in vitro model of placental origin.
Exposure of JEG3 cells to either 5 ng/mL TGF1 or 3
for 3 and 8 hours significantly increasedASAH1mRNA
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levels (Figure 2A). ASAH1 protein levels were also
markedly increased in JEG3 cells following a 24-hour
exposure to TGF1 or 3 (Figure 2B).
Classical TGF signalling is initiated by TGF bind-
ing to a type II serine threonine kinase receptor that
subsequently recruits and phosphorylates activin recep-
tor-like kinase 5 (ALK5), leading to SMAD2/3 activa-
tion (22). To determine whether ALK5/SMAD2 signal-
ling was responsible for mediating the TGF effect on
ASAH1 expression, we treated JEG3 cells with 5M
SB431542, an inhibitor that selec-
tively blocks ALK5 signalling.
SB431542 treatment indeed re-
versed the TGF1 and 3 stimula-
tory effect on ASAH1 protein ex-
pression (Figure 2C). To confirm
that SB431542 acted as an ALK5
inhibitor we measured SMAD2
phosphorylation after TGF1 and
3 stimulation. SB431542 treat-
ment entirely abrogated TGF1/3-
induced SMAD2 phosphorylation
(Figure 2C)while totalSMAD2levels
remained unchanged (Figure 2C). We
then knocked down SMAD2 expres-
sion by transiently transfecting JEG3
cells with either empty vector (pSuper)
or a plasmid encoding SMAD2 siRNA.
Consistent with the SB431542 results,
TGF-induced expression of ASAH1
was significantly reduced in siSMAD2-
transfected cells relative to control
empty vector (Figure 2D). Expectedly,
pSMAD2 expression was decreased in
siSMAD2-transfected cells (Figure 2D).
Having demonstrated a TGF/
ALK5-mediated effect on ASAH1
expression in JEG3 cells, we next as-
sessed the role of TGF1/3 in regu-
lating ASAH1 expression in human
villous explants, a well-established
ex vivo placental model (17). Given
that TGF1 and 3 are highly ex-
pressed in the human placenta dur-
ing early gestation (8, 23), we rea-
soned that blocking ALK5 signalling
with SB431542 would be a suitable
experimental approach. Exposure of
villous explants to SB431542 inhib-
ited ALK5 signalling as demon-
strated by reduced pSMAD2 and
ASAH1 expression compared with
control vehicle-treated explants
(Figure 2E). To establishwhether the reduction inASAH1
levels in SB431542-treated villous explants would affect
CER turnover we alsomeasured CER levels.We observed
significant increases in C18-Cer(d18:1/18:0), C20-
Cer(d18:1/20:0), andC24-Cer(d18:1/24:0) in SB431542-
treated explants relative to controls (Figure 2F). Collec-
tively, these data are in support of the TGF/ALK5/
SMAD2 pathway regulating CER levels via ASAH1 in the
human placenta.
Figure 1. Ceramide levels and ASAH1 expression are altered in placentae from IUGR
pregnancies. A, CER levels measured by LC-MS/MS in placental tissue from IUGR pregnancies
compared with age-matched preterm controls (PTC). Numbers indicate the number of
carbons in the fatty acid chain bound to sphingosine (d18:1) backbone (IUGR, n  33; PTC,
n  23; *, P  .05). B, Western blot analysis of human placental tissue identified ASAH1 as
a band of 40 kDa. Incubation with a blocking peptide selectively competed for the 40 kDa
band. C, Representative immunoblot showing ASAH1 expression in IUGR placentae
compared with PTC placentae. C, (Right panel) densitometric analysis of ASAH1 protein
expression in IUGR and PTC placentae normalized to -actin and expressed as a fold change
relative to PTC (IUGR, n  14; PTC, n  11, **, P  .01). D, ASAH1 activity in IUGR vs PTC
placentae (IUGR, n  6; PTC, n  6; *, P  .05). E, ASAH1 spatial localization in IUGR and
PTC placental sections (IUGR, n  3; PTC, n  3). Images are shown at 40 magnifications.
Negative IgG; ST, syncytiotrophblast.
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Figure 2. TGF1 or 3 treatment increases ASAH1 expression in an ALK5/Smad2-dependent manner in JEG3 cells and in villous explants.
A, ASAH1 mRNA expression in JEG3 cells treated with 5 ng/mL TGF1 or 3 relative to control vehicle (V) (n  3; **, P  .01). B, (Upper panel)
representative immunoblot for ASAH1 in JEG3 cells following 24-h exposure to TGF1, TGF3, or control vehicle (V). B, (Bottom panel)
densitometric analysis of ASAH1 protein expression in TGF1/3-treated JEG3 cells. Data are expressed as a fold change relative to control (V)
vehicle (n  8; *, P  .05; **, P  .01; and ***, P  .001). C, (Right panel) representative immunoblot for ASAH1, pSMAD2, and SMAD2
expression in TGF1/3-treated JEG3 relative to control vehicle in the presence or absence of ALK5-inhibitior SB431542 (5M). C, (Left panel)
densitometric analysis of ASAH1 protein expression in TGF1/3-treated JEG3 cells in the presence or absence of SB431542. Data are expressed as
a fold change relative to control vehicle (V) (n  3; *, P  .05; **, P  .01). D, Representative immunoblot of ASAH1, pSMAD2 protein expression
in pSuper- and siSMAD2-transfected JEG3 cells treated with control vehicle (V) or TGF1/3. D, (Right panel) densitometric analysis of ASAH1
protein levels in siSMAD2-transfected JEG3 cells normalized to ACTB and expressed as a fold change relative to control vehicle (V) (n  3; *, P 
.05, **, P  .01; ***, P  .001). E, (Right panel) representative immunoblot showing ASAH1, pSMAD2, and total SMAD2 expression in villous
explants treated with control vehicle (V) or ALK5 inhibitor SB431542 (10M). E, (Left panel) densitometric analysis of ASAH1 protein expression in
SB431542-treated villous explants normalized to ACTB and expressed as a fold change relative to control vehicle (V) treatment (n  5 explants;
*, P  .05). F, Ceramide levels measured by LC-MS/MS in human villous explants following SB431542 treatment, expressed as a fold change
relative to control vehicle (V) (n  5 explants; *, P  .05; ***, P  .001).
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Sphingosine metabolism is disrupted in IUGR
pregnancies
In line with increased ASAH1 expression/activity and
decreased CER levels in IUGR, sphingosine (SPH) levels
were significantly increased in IUGR compared with PTC
placentae (Figure 3A). Given that sphingosine can be fur-
ther modified by SPHK to produce S1P we next examined
SPHK1 expression. Real-time PCR revealed a marked de-
crease in SPHK1mRNA levels in IUGR vs PTC placentae
(Figure 3B). Western blotting of human placental lysates
identified SPHK1 as a single band at 49 kDa. In agreement
with mRNA findings, SPHK1 protein levels were mark-
edly decreased in IUGRplacentae (Figure 3C) and thiswas
accompanied by a significant decrease in SPHK1 activity
(Figure 3D). Labor, gestation, and sex did not affect
SPHK1expression (Supplemental Figure 2). Thus, SPHK1
expression and activity are markedly reduced in IUGR
placentae independent of mode of delivery, gestation, and
fetal sex, thereby contributing to the accumulation of
SPH. SPH is a known inducer of apoptosis (24); hence, it
is plausible that elevated SPH seen in
IUGR may contribute to increased
placental cell death found in IUGR.
Cleaved-caspase3 analysis confirmed
the augmented levels of apoptotic cell
death in IUGR placentae (Figure 3E).
Signalling via ALK1 regulates
SPHK1 expression
To determine whether, similarly
to ASAH1, altered TGF signalling
contributes to impaired SPHK1 ex-
pression in IUGR, JEG3 cells were
exposed to either TGF1 or 3.
Real-time PCRandWestern blotting
demonstrated that TGF1 or 3-
treated JEG3 cells had significantly
reduced SPHK1mRNA and protein
levels compared with control vehi-
cle-treated cells (Figure 4A, B).
Although TGF-induced SMAD2
phosphorylation in JEG3 cells was
inhibited by SB431542, ALK5 inhi-
bition by SB431542 did not reverse
the negative effect of TGF1/3 on
SPHK1 expression (Supplemental
Figure 3A). Knockdown of SMAD2
expression with SMAD2 siRNA did
also not reverse the TGF3 (and to a
lesser extent TGF1) induced reduc-
tion of SPHK1 in JEG3 cells (Supple-
mental Figure 3B). To further rule
out ALK5 signalling in regulating
placental SPHK1 levels we examined SPHK1 expression
in villous explants following SB431542 treatment. West-
ern blotting revealed reduced SMAD2 phosphorylation
following SB431542 treatment, but no significant changes
in SPHK1 expression (Supplemental Figure 3C). In addi-
tion, no differences in SPH levels in SB431542-treated vs
control vehicle–treated explants were observed (Supple-
mental Figure 3D). Thus, in contrast with ASAH1, the
ALK5/SMAD2pathway seems not tomediate the effect of
TGF on SPHK1 expression.
TGFs have also been shown to activate another type 1
receptor/SMAD pathway (25), namely ALK1 that induces
SMAD1/5 phosphorylation. Hence, JEG3 cells were ex-
posed toTGF1/3 in thepresenceor absenceof10Mof the
ALK1 inhibitor dorsomorphin. Surprisingly, dorsomorphin
inhibited pSMAD1 phosphorylation as well as SPHK1 ex-
pression in unstimulated cells, suggesting that ALK1 signal-
ling is crucial for maintaining basal SPHK1 expression (Fig-
ure 4C). Exposure of JEG3 cells to TGF1/3 stimulated
Figure 3. Sphingosine levels and SPHK1 expression are altered in placentae from IUGR
pregnancies. A, Sphingosine levels measured by LC-MS/MS in placental tissue from IUGR and
PTC pregnancies (IUGR, n  26; PTC, n  17; *, P  .05). B, SPHK1 mRNA expression in
placentae from IUGR relative to PTC pregnancies as determined by qPCR (IUGR, n  10; PTC,
n  9; **, P  .01). C, SPHK1 protein expression in IUGR relative to PTC placentae (IUGR,
n  14; PTC, n  11; **, P  .01). D, SPHK1 activity in IUGR placentae compared with PTC
placentae expressed as a fold change relative to PTC (IUGR  10; PTC  5; *, P  .05). E,
Cleaved caspase 3 (cl-CASP3) protein expression in placentae from IUGR relative to PTC
pregnancies.
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SMAD1 phosphorylation that was reduced by dorsomor-
phin (Figure4C), indicating thatALK1signalling isactivated
by TGF1/3. However, dorsomorphin did not reverse the
negative effect of TGF3 on SPHK1 expression. In contrast,
SPHK1 expression was further reduced in both TGF1/3
plus dorsomorphin groups compared with TGF1/3 alone
(Figure 4C). These data suggest that TGF opposes positive
ALK1 signalling toward SPHK1 expression. To confirm
ALK1-positive signalling toward SPHK1 expression we
treatedJEG3cellswithbonemorphogenicprotein9(BMP9),
a ligand that binds with high affinity to ALK1 (26). BMP9
increased SPHK1 expression that was abrogated by dorso-
morphin (Figure4D),underscoringpositiveALK1signalling
in controlling SPHK1 expression. To rule out other TGF-
stimulated signalling pathways we repeated similar experi-
mentswith pharmacological inhibitors (U0126, SN239063,
and SP600125) of MAPK/ERK, p38MAPK, and JNK/
MAPK, respectively. None of the inhibitors reversed the
TGF-induced reduction in SPHK1 expression (Supple-
mental Figure 3E).
Figure 4. TGF3 reduces SPHK1 expression in JEG3 via ALK1, but not ALK5 signalling. A, SPHK1mRNA levels in JEG3 cells following 5 ng/mL TGF1/3
treatment relative to control vehicle (V) as measured by qPCR (n 4; *, P .05; ***, P .001). B, SPHK1 protein levels in TGF1/3 and control vehicle (V)-
treated JEG3 cells (upper panel) (n 9; *, P .05; ***, P .001). C, Representative immunoblots for SPHK1, pSMAD1, and total SMAD1 expression in TGF1/
3- and control vehicle (V)-treated JEG3 cells in the presence or absence of the ALK1 inhibitor 10MDorsomorphin. C, (Right panel) densitometric analysis of
SPHK1 protein expression in TGF1/3-treated JEG3 cells in the absence or presence of Dorsomorphin normalized to ACTB and expressed as a fold change relative
to control (V) vehicle (n 3; *, P .05; ***, P .001). D, Representative immunoblot and densitometric analysis for SPHK1 in BMP9 treated JEG3 cells in the
presence or absence of Dorsomorphin (n 3; *, P .05; ***, P .001).
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Changes in ALK1 and ALK5 expression in IUGR
placentae
We next examined ALK5/pSMAD2 and ALK1/
pSMAD1 expression in IUGR placentae. We found in-
creased ALK5 mRNA and protein levels in IUGR placen-
tae when compared with PTCs and TCs (Figure 5A, B).
Immunofluorescence staining showed strong positive
ALK5 and pSMAD2 immunoreactivity primarily in the
trophoblast layer of placental villi from IUGRpregnancies
(Figure 5C), suggesting increased activation of ALK5-me-
diated TGF signalling in IUGR (Figure 5C, lower panel).
In stark contrast, ALK1 protein levels were markedly de-
creased in IUGRplacentae relative to controls (Figure5D).
Immunofluorescence staining corroborated the reduction
of ALK1 and its downstream signal
pSMAD1 in IUGR placentae com-
pared with PTC. Intriguingly, their
expression was mainly restricted to
chorionic vessels (Figure 5E).
Discussion
Bioactive sphingolipids are key reg-
ulators of cell fate events during or-
ganogenesis and in disease status. In
the present study, we report that al-
teration in ASAH1 and SPHK1 ex-
pression and activity tilts the SPH/
S1Pbalance towardprodeath SPH in
placentae from severely IUGR preg-
nancies. Using human villous ex-
plants and human choriocarcinoma
JEG3 cells we further demonstrate
that TGF1/3 are primarily respon-
sible for regulating ASAH1 and
SPHK1 expression via distinct ALK/
SMAD-signalling pathways. TGF1/3
signals via ALK5/SMAD2 to induce
ASAH1 protein expression, whereas
positive ALK1/ALK5/SMAD1 sig-
naling toward SPHK1 is opposed by
TGF1/3. Of clinical significance,
we report differentially altered ALK/
SMADsignal pathways in IUGRthat
contribute to the impaired placental
sphingolipidmetabolism found in this
pathology.
Changes in the expression/activ-
ity of sphingolipid metabolizing en-
zymes that result in lipid accumula-
tion are common to a number of
human pathologies including lyso-
somal storage disorders, and cancers (27). Similar to
IUGR placentae, increased ASAH1 expression/activity
has been reported in human prostate cancer and melano-
mas (28, 29). The enhanced CER degradation by elevated
ASAH1 expression/activity in IUGR placentae is in stark
contrast with preeclampsia where deficient ASAH1 ex-
pression/activity leads to increased CER levels (16). These
distinctive sphingolipid signatures are not surprising given
that preeclampsia and IUGR represent placental disorders
with different trophoblast cell phenotypes (14, 30).
BreakdownofCERbyASAH1 is required for SPHpro-
duction that, in turn, is phosphorylated to prosurvival S1P
by SPHK1. In vitro studieswithmurine fibrosarcoma cells
Figure 5. ALK5/pSmad2 and ALK1/pSmad1 are differentially expressed in placentae from IUGR
pregnancies. A, ALK5 mRNA levels in IUGR placentae compared with PTC and TC placental tissue
normalized to 18S and expressed as a fold change relative TC as detected by qPCR (TC, n  4;
PTC, n  8; IUGR, n  10; *, P  .05). B, ALK5 protein expression in IUGR placentae compared
with PTC and TC (IUGR, n  22; PTC, n  12; TC, n  10; *, P  .05). C, Representative
immunofluorescence images for ALK5 and pSMAD2 in IUGR and PTC placental tissue sections.
D, ALK1 protein expression levels in IUGR and PTC placentae. E, Representative immunofluo-
rescence images for ALK1 and pSMAD1 in placental tissue sections from IUGR and PTC. Images
are shown at 40 magnification.
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have shown that elevated ASAH1 lead to reduced cer-
amide levels as well as suppression of apoptosis (31). Sim-
ilar to cancer cells, enhanced CER degradation via in-
creased ASAH1 expression/activity in IUGR placentae
implies an adaptive mechanism aimed at maintaining
proper trophoblast cell homeostasis. However, SPH con-
version into S1P in IUGR placentae is prevented by a
marked reduction in SPHK1 expression/activity. In con-
trast with prosurvival S1P, SPH is a potent cell death
inducer (24). Although CER overload is responsible for
increased trophoblast cell death in preeclampsia (16), it is
plausible that SPH accumulation in IUGR in part accounts
for elevated trophoblast cell death rates seen in this disease
(Figure 3E). Thus, disrupted sphingolipid metabolism may
differentially contribute to improper placentation typical of
these pathologies.
SPHK is a highly conserved enzyme that exists in two
isoforms, SPHK1 and SPHK2. SPHK1 is expressed and
functions in the cytosol, whereas SPHK2 expression is
restricted to the nucleus (32). SPHK1 is involved in pro-
moting cell survival, angiogenesis, and tumorigenesis (33).
During pregnancy, uterine SPHK1 expression is thought
to mediate growth and differentiation of uterine tissues
(34) and SPHK1 gene disruptions causes defective decidu-
alization (34). In addition, female homozygous knockouts
for SPHK1 have a massive uterine accumulation of SPH
(35). These pregnancy-related phenotypic findings in de-
fective SPHK1 rodent models agree with our data in hu-
mans, suggesting that an altered sphingolipid metabolism
may contribute to placental insufficiency typical of IUGR.
Proinflammatory cytokines, growth factors, and oxi-
dative stress have been shown to impinge on the sphingo-
lipid rheostat (36). To date only a handful of reports have
shown TGF regulation of sphingolipid metabolism;
however, none of these studies have examined the pla-
centa. Toour knowledgewe are the first to report aTGF-
mediated regulation of ASAH1 expression in trophoblast
cells or any other cell types for that matter. Sato et al (11)
reported decreased CER levels following TGF1 treat-
ment of serum-starved fibroblasts; however, they did not
examine whether this was due to changes in ASAH1 ex-
pression/activity.Our data strongly suggest that TGF1/3
signalling viaALK5/SMAD2 increasesASAH1expression
resulting in augmented conversion of CER into SPH.
Reports have shown that TGF1 up-regulates SPHK1
expression and activity, thereby protecting cells from ap-
optosis (12, 36, 37). In contrast, we observed a marked
decrease in SPHK1 following exposure to TGF3, but less
with TGF1. No studies have ascribed a role for TGF3
in sphingolipid metabolism; yet, in the present study,
TGF3 had themost profound effect on bothASAH1 and
SPHK1 expression in JEG3 cells. Although TGF iso-
forms share overlapping functions, TGF3 has been
shown to be an important regulator of human placenta-
tion (8). This unique role for TGF3 in trophoblast dif-
ferentiation may explain why we observed a more pro-
found effect on sphingolipid metabolizing enzymes with
TGF3 than TGF1.
Herein, we found that inhibition of canonical ALK5-
mediated signalling had no effect on SPHK1 expression
but that selective blocking of ALK1 activity with dorso-
morphin negatively affect SPHK1 expression and func-
tion. Studies using endothelial cells have identified ALK1
as an additional type I TGF receptor, which requires
ALK5 for its function (38). Although ALK5 activates
SMAD2/3, TGF activation of ALK1 leads to phosphor-
ylation of BMP-mediated SMAD1/5 (38). It seems that
ALK5 and ALK1 are not redundant, but rather activate
different SMAD-mediated signalling pathways that pro-
mote angiogenesis (39). Interestingly, S1P, the product of
SPHK1, is proangiogenic. Hence, reduced ALK1 expres-
sion, specifically in the chorionic vessels, together with
negative TGF3 signaling resulting in diminished SPHK1
expression in IUGR may explain the impaired SPH pro-
cessing to S1P, which may result in the hypovascular phe-
notype typical of this pathology. Mutations of the ALK1
gene have been linked to the type II hereditary hemor-
rhagic telangiectasia, a disorder characterized by multi-
Figure 6. Putative model of TGF-mediated regulation of ASAH1 and
SPHK1 expression in IUGR. Canonical TGF signalling involves TGF
binding to a TGF Receptor II and activin receptor-like kinase 5 (ALK5)
or ALK1, which in turn phosphorylate and activate distinct intracellular
SMAD proteins that regulate gene expression. In IUGR elevated ALK5
signalling via SMAD2 increases ASAH1 expression leading to
augmented CER conversion to SPH. Moreover, deficient ALK1
signalling via SMAD1 and its inhibition by TGF3 suppresses SPHK1
expression; thereby further contributing to SPH accumulation in IUGR.
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systemic vascular dysplasia, indicating that ALK1 may
mediate signals important for the formationor remodeling
ofbloodvessels (40, 41).Othershave reported thatALK1-
deficient mice embryos die at mid gestation due to severe
vascular abnormalities and that disruption ofALK1 leads
to dominance of the ALK5 signalling pathway (38). These
studies and our findings support the idea that an imbal-
ance in ALK1 and ALK5 signalling in the IUGR placenta
impairs angiogenesis that in part may be due to a changed
sphingolipid rheostat.
In conclusion, our results suggest that alterations in
expression of the sphingolipid regulatory enzymes
ASAH1 and SPHK1 in IUGR placentae is governed by
TGF3 via different signalling pathways (Figure 6),
thereby leading to accumulation of prodeath SPH and
consequently, contributing to the enhanced cell death and
abnormal angiogenesis, seen in this disorder.
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